Hengrui Medicine (01276.HK): Ruiweilutamide Tablets Receives Drug Clinical Trial Approval Notice

Zhitong Finance APP news, Hengrui Pharmaceuticals (01276.HK) issued an announcement. Recently, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (hereinafter referred to as the "Company") received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration (hereinafter referred to as the "NMPA") regarding Riveprostatamide Tablets, and will conduct clinical trials in the near future.